Recent Updates
Recently added Catalysts

Varicella Virus Vaccine Live

Phase 3

Varicella | Monoclonal antibody | Infectious Disease |Merck & Company, Inc.|Last Updated: Jan 18, 2019

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment100

FDA Designations

No designations recorded

Clinical trial landscape

Varicella Virus Vaccine Live · 1 trial · 1 indication

Phase 3 1
NCT00496327Safety,Tolerability and Immunogenicity of Vaccination With VARIVAX in Healthy Indian Children (V210-056)Varicella
COMPLETED100 Analytics
PHASE3COMPLETED
Safety,Tolerability and Immunogenicity of Vaccination With VARIVAX in Healthy Indian Children (V210-056)
VaricellaUnlock trial analytics

Study Endpoints

Primary Endpoints

Percent of subjects with VZV specific antibody titre>= 5gp ELISA units/ml 6 weeks post-vaccination
6 weeks post-vaccination
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposePREVENTION

Treatment Arms

ArmTypeDescription
1EXPERIMENTALOpen label

Interventions

NameTypeDescription
Varicella Virus Vaccine Live (Oka-Merck)BIOLOGICALVARIVAX(TM) (Refrigerated) \[Varicella Virus Vaccine Live (Oka/Merck), Refrigerator-Stable Formulation.\] Subjects enrolled in the study received one 0.5 mL subcutaneous dose of VARIVAX(TM). Frequency is single dose.
Unlock Study Design Details

Eligibility Criteria

Age Range12 Years to 12 Years
SexALL
Healthy VolunteersYes

Inclusion Criteria: * Healthy Children, Between 12 Months And 12 Years Of Age * Parent Or Legal Guardian Should Be Willing And Able To Sign The Informed Consent Form Prior To Entry Into The Study Exclusion Criteria: * Any Immune Impairment Or Deficiency, Neoplastic Disease, Or Depressed Immunity,...

Unlock Eligibility Criteria

Frequently asked questions about Varicella Virus Vaccine Live

What is Varicella Virus Vaccine Live used for?

Varicella Virus Vaccine Live is used for varicella, the disease commonly known as chickenpox. It is a live vaccine designed to protect against this infectious disease. The vaccine is being studied in healthy children aged 12 years and older.

Who makes Varicella Virus Vaccine Live?

Varicella Virus Vaccine Live is developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. Merck is conducting clinical trials to evaluate the vaccine's safety and immunogenicity.

What phase is Varicella Virus Vaccine Live in?

Varicella Virus Vaccine Live is in Phase 3 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. The Phase 3 trial has been completed, and the vaccine remains under clinical investigation.

What clinical trials is Varicella Virus Vaccine Live in?

Varicella Virus Vaccine Live has one completed Phase 3 clinical trial registered as NCT00496327. The trial, titled 'Safety,Tolerability and Immunogenicity of Vaccination With VARIVAX in Healthy Indian Children (V210-056)', enrolled 100 healthy children aged 12 years and older to evaluate the vaccine.

Is Varicella Virus Vaccine Live the same as VARIVAX?

Yes, Varicella Virus Vaccine Live is the same as VARIVAX. The clinical trial NCT00496327 refers to the vaccine as VARIVAX, indicating that VARIVAX is the brand name for this live varicella vaccine developed by Merck.